GPC Feeling the Pressure

Just weeks after disappointing news regarding its potential billion-dollar drug satraplatin was swiftly followed by a class action lawsuit against the company, GPC Biotech has announced plans to cut 15 percent of its workforce.
US-PharmaTechnologist.com